Efficacy and Safety of Tofacitinib for Treatment of Moderate to Severe Active Ulcerative Colitis: First Report from Iran

托法替尼 医学 溃疡性结肠炎 内科学 不利影响 Janus激酶抑制剂 临床试验 胃肠病学 外科 安慰剂 临床研究阶段 类风湿性关节炎 替代医学 疾病 病理
作者
Maryam Jameshorani,Homayoon Vahedi,Anahita Sadeghı,Ali Reza Sima,Amir Anushiravani,Helia Nateghi beige,Masoud Mohammad Malekzadeh,Shokoofeh Naserinejad,Sudabeh Alatab
出处
期刊:Archives of Iranian Medicine [Academy of Medical Sciences, I.R. Iran]
卷期号:24 (5): 354-363 被引量:5
标识
DOI:10.34172/aim.2021.52
摘要

BACKGROUND: Tofacitinib, a selective inhibitor of JAK/STAT pathway, has recently become available in our region. Here, we examined the safety and efficacy of tofacitinib in active ulcerative colitis (UC). METHODS: In a prospective, non-randomized, placebo-free, 52-week clinical trial defined in two phases of induction and maintenance, adult patients with active UC and no response or loss of response to previous conventional treatments, or anti-TNF were recruited (IRCT20181217042020N2). Patients received 10 mg/BID of tofacitinib for 8 weeks. Clinically responding patients were entered into the maintenance phase and received tofacitinib 5 mg/BID for 44 weeks. Clinical evaluation, biochemical tests and endoscopy at time points of baseline, 8, 24 and 52 weeks were performed. The primary outcome was clinical remission at 8 and 52 weeks. RESULTS: Fifty out of 53 enrolled patients completed the induction phase. Clinical response and clinical remission at 8 weeks occurred in 84% and 9.5%, respectively. Forty-two patients who had clinical response entered the maintenance phase. Clinical remission based on the total Mayo score and the partial Mayo score occurred in 38.9% and 55.3% at 24 weeks and in 61.1% and 72.2% at 52 weeks, respectively. There was significant correlation between the total and partial Mayo score with regard to clinical remission in both 24 and 52 weeks. No serious adverse events, no case of herpes zoster, but two cases of deep vein thrombosis were seen. CONCLUSIONS: Our study showed acceptable efficacy and safety for tofacitinib and suggested a correlation between the total Mayo score with partial Mayo score with regard to clinical remission.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
吱吱发布了新的文献求助10
刚刚
刚刚
2秒前
单薄冰安发布了新的文献求助10
2秒前
2秒前
Jerry发布了新的文献求助10
3秒前
正直的博发布了新的文献求助10
3秒前
3秒前
充电宝的应助被mingtian采纳,获得10
3秒前
aaaol发布了新的文献求助10
3秒前
科研通AI6.4的应助被花椰菜采纳,获得10
4秒前
5秒前
Yxianzi发布了新的文献求助10
6秒前
木子发布了新的文献求助30
6秒前
7秒前
Xk发布了新的文献求助10
7秒前
7秒前
8秒前
8秒前
9秒前
王珺完成签到,获得积分10
9秒前
冬笺完成签到 ,获得积分10
10秒前
虚幻的方盒完成签到,获得积分10
11秒前
Ava的应助被欣灵采纳,获得15
11秒前
科研通AI6.3的应助被LIUDAN采纳,获得10
11秒前
搞怪灯泡发布了新的文献求助30
12秒前
Twinkle发布了新的文献求助10
13秒前
linr_terran发布了新的文献求助10
13秒前
斯文败类的应助被超级无敌采纳,获得30
13秒前
Y元郁Y完成签到,获得积分20
13秒前
leoan完成签到,获得积分0
14秒前
14秒前
14秒前
15秒前
15秒前
wufel2完成签到,获得积分0
15秒前
王不留行完成签到 ,获得积分10
16秒前
学霸业的应助被YYYY采纳,获得10
18秒前
大方酶完成签到,获得积分10
18秒前
木子完成签到,获得积分20
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189302
求助须知:如何正确求助?哪些是违规求助? 9576666
关于积分的说明 21849295
捐赠科研通 7787245
什么是DOI,文献DOI怎么找? 3435521
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509